Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.64 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.51 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12806475 | 1.00 | GLP1R (0.64) | GLP1RFOLH1GNPATNOD1 | |
| SCHEMBL12806517 | 1.00 | GLP1R (0.64) | GLP1RFOLH1GNPATNOD1 | |
| SCHEMBL12806523 | 1.00 | GLP1R (0.64) | GLP1RFOLH1GNPATNOD1 | |
| SCHEMBL15507705 | 1.00 | GLP1R (0.64) | GLP1RFOLH1GNPATNOD1 | |
| SCHEMBL15507496 | 1.00 | GLP1R (0.64) | GLP1RFOLH1GNPATNOD1 | |
| SCHEMBL12806418 | 1.00 | GLP1R (0.64) | GLP1RFOLH1GNPATNOD1 | |
| SCHEMBL12806522 | 1.00 | GLP1R (0.64) | GLP1RFOLH1GNPATNOD1 | |
| SCHEMBL24486694 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1 | |
| SCHEMBL8248469 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1 | |
| SCHEMBL12806481 | 0.94 | GLP1R (0.70) | GLP1RFOLH1GNPATNOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150633-B2 | Insulin analogues with an acyl and alkylene glycol moiety | NOVO NORDISK A/S (DK) | 2015-10-06 | — | — | US | disclosed |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | NOVO NORDISK AS (DK) | 2015-07-30 | — | — | US | disclosed |
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | NOVO NORDISK A/S (DK) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098440-A1 | Insulin Analogues with an Acyl and Alkylene Glycol Moiety | IAPP, INSR, IGF1R | GLP1R 7/4885FOLH1 1261/4885GNPAT 2340/4885 |
| US-20150210748-A1 | PROTEASE STABILIZED ACYLATED INSULIN ANALOGUES | IAPP, IDE, LIPE | GLP1R 54/4885FOLH1 524/4885GNPAT 1212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.